

1 **Efficacy of intravenous paracetamol and mannitol in managing chronic**  
2 **post-thoracotomy pain in patients with lung cancer: Study protocol for a single**  
3 **center prospective randomized double-blind controlled trial**

4

5 Xing Lu<sup>1¶</sup>, Junhui Zhou<sup>1¶</sup>, Xi Li<sup>1</sup>, Jie Gao<sup>2</sup>, Siqing Liu<sup>3</sup>, Wei Zhong<sup>1</sup>, Gaoyuan Xi<sup>1</sup>,  
6 Yingchun Guo<sup>1</sup>, Hongdang Xu<sup>4\*</sup>

7

8 <sup>1</sup> Department of Anesthesiology, Henan Provincial Chest Hospital & Chest Hospital  
9 of Zhengzhou University, Zhengzhou, China

10 <sup>2</sup> Department of Anesthesiology, Chinese Academy of Medical Sciences & Peking  
11 Union Medical College, Peking, China

12 <sup>3</sup> The Second Hospital of Tianjin Medical University, Tianjin, China

13 <sup>4</sup> Department of Anesthesiology, Central China Fu Wai Hospital, Central China Fu  
14 Wai Hospital of Zhengzhou University, Heart Center of Henan Provincial People's  
15 Hospital, Zhengzhou, China

16

17 Short title: Intravenous paracetamol and mannitol for post-thoracotomy pain in lung  
18 cancer

19

20 \*Corresponding author

21 Email: [zhicungaoyuan1985@163.com](mailto:zhicungaoyuan1985@163.com) (HX)

22

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

23 ¶ These authors contributed equally to this work and are co-first authors.

## 24 **Funding**

25 This trial is supported by the Henan Provincial Science and Technology Research and  
26 Development Program Joint Fund (Applied Research Category) (No.232103810054).

27 The sponsor and funder had no involvement in the study design, data collection,  
28 management, analysis, and interpretation, writing of the report, or the decision to  
29 submit the report for publication.

## 30 **Competing interests**

31 The authors declare that they have no competing interests.

## 32 **Data availability**

33 During the current study, no datasets were generated or analyzed. All pertinent data  
34 from this study will be accessible upon its completion.

35

## 36 **Abstract**

37 Chronic post-thoracotomy pain is a common complication that affects 20% to  
38 60% of patients who undergo surgery for lung cancer. The persistent pain affects  
39 quality of life and satisfaction with surgery. Intravenous paracetamol and mannitol,  
40 known to have analgesic and antipyretic properties, may help relieve  
41 moderate-to-severe post-operative pain. This trial aims to assess their effectiveness  
42 and safety in managing chronic post-thoracotomy pain in patients with lung cancer.  
43 This prospective double-blind randomized controlled clinical trial will be conducted  
44 at a single center. A total of 856 patients who will undergo thoracoscopic radical

45 surgery for lung cancer will be enrolled and randomly assigned to test (intravenous  
46 paracetamol and mannitol) and control (intravenous normal saline) groups in a 1:1  
47 ratio (428 patients in each group). Efficacy will be evaluated in terms of the incidence  
48 of chronic post-thoracotomy pain at 3 months (primary outcome). Secondary  
49 outcomes will include the dosage of propofol and remifentanyl, numerical rating scale  
50 pain scores, number of times the patient-controlled intravenous analgesia button is  
51 pressed, occurrence of post-operative nausea and vomiting and respiratory depression,  
52 time to first flatus and ambulation after surgery, length of hospital stay, surgeon and  
53 patient satisfaction, and incidence of chronic post-thoracotomy pain at 6 and 12  
54 months after surgery. Quality of daily life will be evaluated at 3, 6, and 12 months  
55 after surgery. Intention-to-treat analysis will also be conducted. The research protocol  
56 has been reviewed and approved by the Medical Thesis Committee of Henan  
57 Provincial Chest Hospital and Chest Hospital of Zhengzhou University on April 29,  
58 2023 (reference: [2023] approval number: [04-06]). The results of this trial will be  
59 communicated to the participants and subsequently submitted for publication in  
60 peer-reviewed journals for wider dissemination. The study has been registered in the  
61 Chinese Clinical Trial Registry on June 27, 2023 (registration number:  
62 ChiCTR2300072869, available at <https://www.chictr.org.cn/>). The protocol version  
63 number is Version 1.1, dated August 20, 2023.

64

## 65 **Introduction**

66 Chronic post-surgical pain (CPSP) is common following surgery at different sites and

67 may develop after abdominal, orthopedic, and cardiothoracic procedures. The surgical  
68 site and methods are the primary factors that influence the incidence of CPSP [1].  
69 Thoracotomy is a procedure that allows access to the thoracic cavity. As this requires  
70 dissection through multiple layers of skin, fat, and muscles, patients experience acute  
71 or chronic pain after surgery; notably, thoracic surgery is associated with the highest  
72 incidence of chronic pain [2]. Chronic post-thoracotomy pain (CPTP) is a persistent  
73 and debilitating condition that affects a substantial number of patients who undergo  
74 surgery for lung cancer. This long-term neuropathic pain mainly occurs around the  
75 incision site [3]. As this is a type of CPSP, it is defined by persistence for at least 3  
76 months after the procedure [4]. CPTP can significantly impact quality of life in  
77 affected patients, and thereby lead to physical and psychological distress; it also  
78 increases subsequent medical expenses and social costs. However, an incomplete  
79 understanding of its pathophysiology, a lack of personalized therapeutic strategies,  
80 absence of standardized assessment criteria, inadequate long-term follow-up, and  
81 deficiencies in interdisciplinary teamwork create substantial challenges to the  
82 effective management of CPTP. Addressing these issues requires further research,  
83 clinical evaluation, and policy support. This may help improve management of the  
84 condition and patient quality of life.

85 Trauma during thoracic surgery typically involves injuries to the costal cartilage,  
86 costovertebral joints, muscles, pleura (due to traction), intercostal nerves, and lung  
87 parenchyma; thoracic drainage tubes are also a source of irritation. In conjunction,  
88 these injuries may contribute to the development of CPTP [5]. Tissue and nerve

89 damage can result in inflammation and edema, and directly cause symptoms of nerve  
90 compression. In addition, the release of inflammatory mediators such as interleukin-6,  
91 interleukin-8, tumor necrosis factor- $\alpha$ , and substance P may lower the pain threshold  
92 by enhancing pain receptor activity. This cascade ultimately results in heightened  
93 sensitization of pain centers in the spinal dorsal horn neurons and cerebral cortex.  
94 Current understanding therefore supports the notion that the pathogenesis of CPTP  
95 involves a combination of somatic, visceral, and neuropathic pain, that is often  
96 accompanied by central nervous system sensitization [6].

97 The presence of intense acute pain following surgery has been identified as one of the  
98 predictive risk factors for the development of CPSP [7]. Anesthesiologists therefore  
99 use a variety of analgesic techniques to alleviate early post-operative pain in patients  
100 undergoing thoracic surgery. Commonly utilized strategies include administration of  
101 thoracic epidural analgesia, intravenous non-steroidal analgesics or opioids, and  
102 ultrasound-guided nerve blocks (such as paravertebral, intercostal nerve, and erector  
103 spinae and serratus anterior plane blocks, among others) [8]. Among these  
104 approaches, ultrasound-guided nerve blocks have gained particular popularity for  
105 post-operative pain management. This may be attributed to their efficacy in providing  
106 analgesia and reducing the need for opioids, both of which potentially decrease  
107 opioid-related adverse effects such as post-operative nausea and vomiting [9].  
108 However, nerve block procedures require considerable skill and are associated with  
109 risks of complications such as pneumothorax, hematoma, and block failure.  
110 Anesthesiologists need to possess a thorough understanding of the position of

111 anatomical structures to address these challenges; this can be particularly demanding  
112 for less experienced practitioners.

113 Paracetamol (acetaminophen) is a 4-p-aminophenol derivative and a type of  
114 acetanilide central antipyretic analgesic. Unlike non-steroidal anti-inflammatory  
115 drugs, it does not cause damage to the gastric mucosa (that causes indigestion) or  
116 kidney. In addition, it does not cause the unpleasant side-effects associated with  
117 opioids such as respiratory depression, nausea, vomiting, constipation, or urinary  
118 retention [10]. Owing to the lesser potential for adverse reactions and high safety, it is  
119 often the first choice for multimodal analgesia after surgery. As per the American  
120 Society of Anesthesiologists Task Force on Acute Pain Management [11],  
121 post-operative patients should receive non-opioid analgesics as first-line drugs in the  
122 absence of any contraindications; opioids are only recommended as auxiliary drugs.

123 The intravenous route is ideal for administration of paracetamol immediately after  
124 surgery, as patients are unable to take oral drugs and/or need rapid pain relief [12].  
125 Previous studies have confirmed that paracetamol injections offer reliable and optimal  
126 analgesic effect, while avoiding the adverse reactions of opioids [13]. A systematic  
127 review and meta-analysis comprising 5 randomized controlled trials (including 2635  
128 patients) evaluated the impact of intravenous acetaminophen on post-operative pain in  
129 those undergoing brain surgery. The results showed that acetaminophen significantly  
130 decreased rescue analgesic consumption, total analgesic use, intensive care unit stay,  
131 and visual analog scale scores, and increased patient satisfaction. Preoperative  
132 administration of intravenous acetaminophen was therefore found to effectively

133 alleviate post-operative pain, reduce analgesic requirements, and improve outcomes in  
134 patients undergoing brain surgery [14]. Another study on patients who underwent  
135 partial mastectomy showed that the analgesic effect of intravenous acetaminophen  
136 was comparable to that of flurbiprofen axetil. However, it was more effective in  
137 controlling movement-induced pain at 3 h after surgery, and demonstrated a lower  
138 incidence of adverse reactions [15]. Yet another study on patients who underwent  
139 video-assisted thoracic surgery demonstrated that the post-operative pain control  
140 offered by intravenous ketorolac and acetaminophen was comparable to that of  
141 morphine. Notably, the combination offered superior pain control compared to  
142 morphine within 2 hours of surgery, and was not associated with any significant  
143 adverse reactions [16]. Nevertheless, there is a paucity of long-term follow-up data  
144 regarding the use of intravenous acetaminophen. The available studies mainly focus  
145 on short-term outcomes, and do not provide crucial long-term follow-up data that are  
146 necessary for assessing the sustained effectiveness and safety profile of this drug.

147 In China, intravenous paracetamol and mannitol was introduced as a novel  
148 analgesic combination in 2022. The primary component is the 4-aminophenol  
149 derivative, which is known for its analgesic and antipyretic properties [17] and  
150 effectively complements opioid analgesics in managing moderate-to-severe  
151 post-operative pain in adult patients. The combined analgesic and anti-inflammatory  
152 effects of intravenous paracetamol and mannitol show promise in preventing the onset  
153 and reducing the progression of CPTP.

154 The aim of this trial is to evaluate and compare the efficacy and safety of

155 intravenous paracetamol and mannitol versus normal saline in alleviating CPTP in  
156 patients with lung cancer. The findings of this trial may help provide crucial clinical  
157 evidence for diversifying management strategies in CPTP; this may in turn improve  
158 treatment outcomes and quality of life.

159

## 160 **Materials and methods**

### 161 **Study design**

162 This single-center prospective randomized double-blind controlled trial will adopt a  
163 parallel group design. It will aim to investigate the efficacy of intravenous  
164 paracetamol and mannitol in managing CPTP among patients who undergo surgery  
165 for lung cancer. To maintain the double-blind design, neither the researchers nor the  
166 participants will be aware of the assigned study group. This will reduce the impact of  
167 subjective bias and ensure objectivity of the results. This trial was registered in the  
168 Chinese Clinical Trial Registry on June 27, 2023, with a registration number of  
169 ChiCTR2300072869.

### 170 **Type of trial**

171 In this parallel-group design trial, participants will be randomly assigned to one of  
172 two groups: test group (receiving intravenous paracetamol and mannitol) and control  
173 group (receiving normal saline).

### 174 **Allocation ratio**

175 Participants will be allocated to either group in a ratio of 1:1; this implies that an  
176 equal number of participants will be allocated to each group.



## 177 **Framework**

178 This superiority trial aims to demonstrate superiority of the intervention agent  
179 (intravenous paracetamol and mannitol) over the control agent (normal saline) in  
180 achieving control of CPTP in patients with lung cancer. The study will assess the  
181 effectiveness of the intervention in reducing pain intensity and improving overall  
182 quality of life (compared to the control). The investigators will strictly adhere to the  
183 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)  
184 guidelines [18] (available for reference on the official website:  
185 <https://www.spirit-statement.org>). The Checklist. SPIRIT checklist can be found in S1  
186 File.

187

## 188 **Participants**

189 This trial will be implemented in an academic hospital, and the data will be  
190 collected in China. The eligibility criteria were determined by a researcher who will  
191 not be associated with the study; the selected criteria are based on patient parameters  
192 at admission. Patients enrolled in this study or their authorized representatives will be  
193 required to sign an informed consent form by a trained researcher prior to initiation of  
194 treatment. The template for the informed consent form can be found in S2 File.

195 Patients will be eligible for inclusion if they: 1) are aged between 18 and 64 years;  
196 2) are diagnosed with lung cancer before surgery (or during surgery via rapid frozen  
197 pathological examination) and are scheduled to undergo thoracoscopic surgery (such  
198 as lobectomy, wedge resection, or anatomic segmentectomy); 3) have American

199 Society of Anesthesiologists grade I–III physical status; and 4) are able to understand  
200 the purpose of the study, agree to participate, and provide written informed consent.

201 Patients will be excluded from this trial if they: 1) only receive conservative  
202 treatment without surgery during hospitalization; 2) have any mental illness or  
203 cognitive impairment and are unable to cooperate with the study requirements; 3) are  
204 diagnosed with severe coagulation dysfunction; 4) have any serious infections; 5) are  
205 dependent on drugs or have a history of long-term use of psychotropic drugs; 6) have  
206 a history of long-term use of steroids or hormonal agents; 7) have Gilbert syndrome;  
207 8) have an inadequate hepatic glutathione reserve due to chronic malnutrition,  
208 anorexia, overeating, or cachexia; 9) suffer from glucose-6-phosphatase  
209 dehydrogenase deficiency, which may lead to hemolytic anemia; and 10) are allergic  
210 to acetaminophen, mannitol, or other anesthetic drugs.

211 Trial participation may be terminated if: 1) patients or their families actively  
212 request for withdrawal from the study during the study period; 2) temporary  
213 thoracotomy closure is necessary during the operation; 3) patients develop severe  
214 heart, brain, liver, or kidney dysfunction after surgery; 4) any of the following events  
215 occur: failed post-operative recovery, automatic discharge, or perioperative death; and  
216 5) patients or their families cannot be contacted on three or more occasions during the  
217 follow-up period.

218

## 219 **Randomization**

220 A computer-generated randomization table will be used to create group random

221 sequences. The random sequences will be generated by independent researchers and  
222 stored in secure electronic files to ensure confidentiality of grouping information. The  
223 generation of random sequences will ensure that participant grouping is random and  
224 unpredictable.

225 Factors for stratification will include age, gender, and pain severity. To reduce  
226 predictability of the random sequence, details of any planned restrictions (such as  
227 blocking) will be outlined in a separate document that cannot be accessed by those  
228 involved in participant enrollment or intervention assignment.

229 The specific steps will be as follows: a) a computer will be used to generate random  
230 numbers in advance; these will be placed in sequentially numbered, sealed, opaque  
231 envelopes which will be managed by designated personnel, b) the patients who meet  
232 the inclusion criteria will be numbered according to the order of enrollment, c)  
233 random numbers will be matched with those of the patient to obtain the allocated  
234 group, d) the results of randomized grouping will be handed over to an anesthesia  
235 nurse, who will provide either acetaminophen and mannitol for intravenous  
236 administration or normal saline. The appearance, packaging, and labeling of these two  
237 drugs will be identical. The syringes will only be labeled as “test drugs” to ensure that  
238 the patients, anesthesiologists, and outcome assessors are unaware of the allocated  
239 group. The anesthesiologist will administer the drugs in sequential order. The random  
240 coding table for the clinical trial (known as a blind bottom) will be kept at the Clinical  
241 Trial Center of the Henan Provincial Chest Hospital & Chest Hospital of Zhengzhou  
242 University.

243      Sequentially numbered opaque sealed envelopes will be used to conceal the  
244      sequence, and each envelope will contain a unique allocation code corresponding to  
245      either the paracetamol and mannitol or normal saline groups. These envelopes will be  
246      opened sequentially by a designated research pharmacist only at the time of  
247      participant enrollment and assignment to ensure allocation concealment. The  
248      allocation codes will not be disclosed to the investigators, participants, or outcome  
249      assessors until study completion. This will prevent disclosure of grouping information  
250      during the allocation process, and ensure appropriate randomization and blinding.

251

## 252      **Blinding**

253      All anesthesiologists, anesthesia nurses, beneficiaries, and personnel involved in data  
254      collection and analysis will be blinded. An anesthesiologist who will be blinded to  
255      patient grouping will conduct the follow-up assessments for acute and chronic  
256      post-operative pain. The Data Monitoring Committee will establish and supervise  
257      emergency unblinding procedures to ensure study integrity.

258

## 259      **Interventions**

### 260      **Anesthetic management**

261      All patients will receive anesthesia as per standardized protocols. Routine  
262      monitoring of the blood pressure, electrocardiogram, and oxygen saturation will be  
263      performed after the patient enters the operating room. Venous access will be  
264      established and invasive arterial blood pressure monitoring will be performed. All

265 patients will be administered combined intravenous and inhalational anesthesia. The  
266 following drugs will be administered intravenously during induction: midazolam  
267 (0.04 mg/kg), etomidate (0.3 mg/kg), sufentanil (0.4  $\mu\text{g}/\text{kg}$ ), and rocuronium (0.8  
268 mg/kg). Double-lumen endotracheal intubation will then be performed under visual  
269 guidance for mechanical ventilation. Following successful tracheal intubation, right  
270 internal jugular vein cannulation will be performed under ultrasound guidance. The  
271 bispectral index will be monitored continuously during surgery to ensure that the  
272 values are maintained within a range of 40–60. Inhalational sevoflurane (1%) will be  
273 administered along with propofol (4–8  $\text{mg}\cdot\text{kg}^{-1}\cdot\text{h}^{-1}$  by continuous infusion),  
274 remifentanil (0.05–0.2  $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ), and rocuronium (0.3–0.6  $\text{mg}\cdot\text{kg}^{-1}\cdot\text{h}^{-1}$ ). The  
275 tidal volume, respiratory rate, positive end-expiratory pressure, and fraction of  
276 inspired oxygen will be adjusted as appropriate. Balanced crystalloid fluids will be  
277 continuously infused at a rate of 3  $\text{ml}\cdot\text{kg}^{-1}\cdot\text{h}^{-1}$  to maintain urine outputs of  $> 0.5$   
278  $\text{ml}\cdot\text{kg}^{-1}\cdot\text{h}^{-1}$ . Rocuronium will be discontinued 30 min before the end of surgery, and  
279 sugammadex will be used for reversing neuromuscular blockade. The double-lumen  
280 endotracheal tube will then be removed, and a patient-controlled intravenous  
281 analgesia (PCIA) pump will be connected to the intravenous access before  
282 transferring the patient to the post-anesthesia care unit (PACU). All patients will  
283 undergo thoracoscopic radical resection of the malignant lung lesion, and the  
284 procedures will be performed by the same group of surgeons.

## 285 **Study interventions**

286 Patients in the test group will be administered intravenous paracetamol (500 mg)

287 and mannitol 15 min before the end of the operation; they will also be administered  
288 intravenous paracetamol (500 mg) and mannitol on post-operative days 1 and 2,  
289 respectively. Patients in the control group will be administered intravenous normal  
290 saline (50 mL) at the same time points.

291

## 292 **Pain management**

293 Patients in both groups will be administered intravenous oxycodone (5 mg) 15 min  
294 before the end of surgery and PCIA immediately after surgery. The medications in the  
295 analgesic pump will include sufentanil (2.5 µg/kg) and tropisetron (10 mg), and will  
296 be diluted with normal saline to achieve a total volume of 100 mL. The following  
297 analgesic pump parameters will be used: background dose: 2 µg/h, single dose: 2  
298 µg/time, and lockout time: 15 min. The patients will be instructed to press the button  
299 on the intravenous analgesia pump (as a remedial analgesic measure) when the  
300 numeric rating scale (NRS) scores for pain will reach  $\geq 4$  points.

301

## 302 **Outcome measures**

303 The investigators will communicate with each patient on preoperative day 1, and  
304 will provide guidance regarding the use of PCIA pumps. The NRS will be used to  
305 evaluate pain intensity in all cases [19]. In this context, the NRS is a commonly used  
306 scoring tool that helps assess the intensity of pain experienced by patients. The  
307 intensity is scored on a scale of 0 to 10, where 0 and 10 indicate no pain and the most  
308 severe pain, respectively. Patients will be asked to select a number to describe their

309 current level of pain. Usually, scores of 0, 1–3, 4–6, 7–9, and 10 indicate no, mild,  
310 moderate, severe, and the most severe pain, respectively.

311 Efficacy will be measured in terms of the incidence of CPTP at 3 months after  
312 surgery; this will be the primary outcome measure of this study. Individuals who meet  
313 the diagnostic criteria for CPSP based on the International Association for the Study  
314 of Pain (International Classification of Diseases-11) standards will be recruited [4].  
315 Notably, CPSP is defined as pain that persists or increases in intensity for more than 3  
316 months following surgery or tissue injury (including any trauma such as burns). The  
317 pain may not be limited to the original surgical or injury site, and may radiate to the  
318 entire area innervated by the nerves that supply that region (e.g., deep somatic or  
319 visceral tissues). Other potential causes of pain, such as acute or chronic infections,  
320 malignant tumors, or pre-existing chronic pain conditions must be excluded before a  
321 diagnosis of CPSP can be made. Although the pain is typically neuropathic by nature,  
322 and neuropathic pain mechanisms play a significant role in the pathogenesis, the  
323 condition should be diagnosed as CPSP and not neuropathic pain. The etiology needs  
324 to be identified, and a diagnosis of chronic primary pain should be made if the cause  
325 cannot be determined.

326 The secondary outcomes will include the dosage of propofol and remifentanil used;  
327 NRS pain scores at PACU entry, 30 min after PACU entry, and after surgery (at 12 h,  
328 24 h, and 48 h); number of times the PCIA button is pressed within 24 h and 48 h  
329 after surgery; the occurrence of post-operative nausea and vomiting, and other adverse  
330 reactions including headache, insomnia, itching, respiratory depression, excessive

331 sedation, urinary retention, allergic reactions, liver injury, and kidney injury;  
332 post-operative bowel movement and ambulation times; length of hospital stay;  
333 surgeon and patient satisfaction; and the incidence of CPTP at 6 and 12 months after  
334 surgery.

335 In the context of post-operative follow-up, the NRS pain scores can be used during  
336 telephone interviews conducted at 3, 6, and 12 months after surgery. These interviews  
337 will mainly focus on the assessment of any pain experienced by the patient at the  
338 surgical site (NRS score > 0).

339 The impact of pain on patient quality of daily life will also be evaluated, and the  
340 degree will be categorized as follows: no, mild, moderate, and severe [20]. The level  
341 of intervention required to manage the pain will also be assessed using the following  
342 grading system:

343 Grade A: No intervention required

344 Grade B: Rest or reduction in activity

345 Grade C: Self-administered medications

346 Grade D: Medical help needed from a healthcare professional

347 A range of efficacy and adverse outcome variables will be selected as observational  
348 indicators to comprehensively assess differences between the control and intervention  
349 groups. This will help evaluate the efficacy of intravenous paracetamol and mannitol  
350 in the management of CPTP. These outcome variables will not only help in presenting  
351 the data, but will also reflect the critical impact on patient health and post-operative  
352 recovery. The incidence of CPTP at 3 months after the procedure was selected as the



353 primary outcome variable, as this parameter directly reflects the effectiveness of  
354 post-operative pain management; this in turn has significant influence on patient  
355 quality of life and the recovery process. Adverse outcome variables such as  
356 post-operative nausea and vomiting and respiratory depression, among others (which  
357 are common post-operative complications) were selected for this trial. Assessment of  
358 the incidence of these complications may offer a more comprehensive understanding  
359 on the safety and practicality of the intervention measures.

360

## 361 **Adverse events**

362 Patient safety will be closely monitored throughout the study. Adverse events and  
363 side effects will be assessed and recorded using a standardized evaluation tool. These  
364 events and side effects may include drug allergies, abnormal liver function, and renal  
365 dysfunction. Any adverse events or side effects will be promptly reported to the study  
366 team and appropriate measures will be taken to ensure patient safety.

367 An independent safety monitoring committee will be established to oversee and  
368 evaluate patient safety throughout the study. This committee will review all reported  
369 adverse events and side effects and provide recommendations for any necessary  
370 adjustments to the study protocol.

371

## 372 **Auditing**

373 The trial conduct will be regularly audited by an independent team to ensure  
374 compliance with the protocol, Good Clinical Practice (GCP) guidelines, and

375 regulatory requirements. Audits will be conducted quarterly, reviewing study  
376 documentation and verifying data accuracy and completeness through on-site visits.  
377 Any deviations will be documented and addressed promptly. The auditing process  
378 will be independent from investigators and the sponsor, reporting directly to the  
379 Institutional Review Board (IRB). Audit findings will be used to identify areas for  
380 improvement and implement corrective actions to ensure study validity and reliability.

381

## 382 **Study protocol and data collection**

383 Recruitment, intervention, assessment, and participant visits will be performed as per  
384 the following schedule:

### 385 **Enrollment**

386 Patients will be enrolled over a period of 12 months, between July 1, 2023 and April  
387 1, 2024. The flow chart of the trial is shown in Figure 1.

### 388 **Interventions**

389 Patients will receive the assigned intervention (intravenous paracetamol and mannitol  
390 or normal saline) during thoracoscopic radical surgery for lung cancer.

### 391 **Assessments**

392 Primary outcome assessment for the incidence of CPTP will be performed at 3  
393 months after surgery. Secondary outcome assessments (including dosage of propofol  
394 and remifentanyl, NRS pain scores, number of times the PCIA button is pressed,  
395 occurrence of post-operative nausea and vomiting, respiratory depression, time to first  
396 flatus and ambulation, length of hospital stay, surgeon and patient satisfaction, and

397 incidence of CPTP at 6 and 12 months after surgery) will be conducted at specific  
398 time points as outlined in the study protocol.

### 399 **Participant visits**

400 Participants will be followed up at 3, 6, and 12 months after surgery to evaluate their  
401 quality of daily life. Fig 1 shows the schedule of enrollment, interventions,  
402 assessments, and participant visits. This table provides a visual representation of the  
403 study timeline and can help ensure adherence to the SPIRIT guidelines.

404

### 405 **Data management and monitoring**

406 In this clinical trial, meticulous planning and execution of data entry, coding, security,  
407 and storage procedures are essential for safeguarding the integrity and confidentiality  
408 of research data. A robust data management framework will be employed for this trial,  
409 and it will be overseen by a dedicated team of experts. Key components of this  
410 framework will include an electronic data capture (EDC) system for data entry,  
411 stringent quality control measures such as double data entry by independent personnel,  
412 and rigorous data validation checks to uphold data accuracy. Data management will  
413 involve the following specific operational processes:

#### 414 **Data entry procedures**

415 Trained research personnel will input data into a secure EDC system, and a dual data  
416 entry process will be employed to minimize errors. In cases of discrepancies, data  
417 entry operators will perform source data verification to ensure accuracy and  
418 consistency.

## 419 **Coding practices**

420 All collected data will be systematically coded using a standardized coding manual to  
421 facilitate uniformity and precision in subsequent data analysis. To protect patient  
422 confidentiality, any personally identifiable information will be anonymized and  
423 replaced with unique study identification numbers.

## 424 **Data security measures**

425 Access to the study database will be strictly controlled and limited to authorized  
426 personnel. Data will be stored securely on protected servers with restricted access  
427 controls and regular backups to prevent data loss or unauthorized access.

## 428 **Data storage protocols**

429 Electronic data will be housed in a password-protected database with encryption  
430 protocols to uphold confidentiality and data security. Physical copies of sensitive  
431 study documents will be stored in locked filing cabinets within a secure office  
432 environment.

## 433 **Enhancing data quality**

434 The EDC system will be equipped with range checks to validate data values; this will  
435 ensure accuracy and completeness. Routine data monitoring and quality control  
436 assessments will be conducted to promptly identify and rectify any discrepancies or  
437 missing entries.

## 438 **Availability of data management procedures**

439 Detailed data management protocols including the areas of data entry, coding,  
440 security, and storage guidelines have been comprehensively outlined in the Data

441 Management Plan document. This document, which delineates specific procedures for  
442 handling research data, can be obtained upon request from the principal investigator  
443 or the research team.

#### 444 **Data collection plan: retention**

445 During the informed consent process, we will provide detailed information to all  
446 participants about the study objectives, procedures, potential risks, and benefits. To  
447 ensure participant retention and progress monitoring, we will schedule regular  
448 follow-up visits or phone calls, reminding them of subsequent appointments.  
449 Additionally, we will assign a dedicated study coordinator to address participants'  
450 concerns, answer questions, and provide necessary support throughout the study.

#### 451 **Data monitoring: formal committee**

452 The Data Monitoring Committee (DMC) will consist of members with diverse  
453 professional backgrounds, including clinical experts, statisticians, and independent  
454 ethics experts, ensuring a comprehensive and proficient evaluation of research data.  
455 The roles and responsibilities of the DMC will be clearly outlined, emphasizing their  
456 duties in monitoring data integrity, accuracy, and safety, evaluating interim analysis  
457 results, and providing impartial advice. A structured reporting mechanism will be  
458 established to keep the research team and stakeholders informed about the study's  
459 progress and potential issues. The independence of the DMC from the sponsor will be  
460 explicitly stated, upholding the credibility and transparency of research data and  
461 ensuring the reliability of the findings of this trial.

462

## 463 **Sample size calculation**

464 The sample size for this study was estimated based on the incidence of CPSP in  
465 patients who undergo surgery for lung cancer at 3 months after surgery (the primary  
466 indicator for evaluation of efficacy). In this randomized controlled trial, the  
467 experimental group will receive intravenous paracetamol and mannitol and the control  
468 group will receive normal saline. Studies have shown that the incidence of CPTP  
469 ranges from 25% to 57% [3]. It may therefore be assumed that 50% of patients in the  
470 control group would develop CPTP at 3 months after surgery. As the pre-trial showed  
471 the incidence of CPSP in the trial group to be 40%, this was set as the incidence rate  
472 for sample size calculation. Based on a bilateral  $\alpha$  value of 0.05 and power (1- $\beta$ ) of  
473 0.8, the sample size ratio between the experimental and control groups was calculated  
474 to be 1:1. The sample size was estimated using R, as per the method proposed by  
475 Chow et al. [21]. Calculations showed the required sample size in each (intervention  
476 and control) group to be 385 cases. On considering a 10% loss-to-follow-up rate, a  
477 minimum of 428 cases will be required in either group; a total of 856 cases will  
478 therefore be included in this trial.

479

## 480 **Statistical analysis**

481 SPSS 19.0 statistical software (IBM Corporation, Armonk, NY, USA) will be used for  
482 all statistical analyses. The two-tailed  $P$  value will be used to test for statistical  
483 significance;  $P < 0.05$  will be considered statistically significant. The following  
484 statistical analysis methods will be employed:

## 485 **Descriptive analysis**

486 Descriptive statistical analysis will be performed using the demographic variables of  
487 the study population including age, sex, and weight. The mean and standard deviation  
488 will be reported for continuous variables, and the frequency and percentage will be  
489 reported for categorical variables. Normality will initially be tested using the Shapiro–  
490 Wilk test. Data conforming to a normal distribution will be presented as means  $\pm$   
491 standard deviation; other data will be presented as medians with interquartile ranges.

## 492 **Baseline comparisons**

493 The t- or Mann–Whitney U tests (depending on data normality) will be used to  
494 compare baseline continuous variables in either group. The chi-square or Fisher’s  
495 exact tests will be used to compare intergroup differences between categorical  
496 variables.

## 497 **Primary outcome analysis**

498 The primary outcome measure, namely, the incidence of CPTP at 3 months after  
499 surgery, will be compared between the test and control groups using appropriate  
500 statistical tests (the chi-square or Fisher’s exact tests). Logistic regression may be  
501 employed to adjust for potential confounders, as appropriate.

## 502 **Secondary outcome analysis**

503 For continuous variables (such as the dosage of propofol and remifentanyl, NRS pain  
504 scores, number of times the PCIA button is pressed, time to first flatus and ambulation  
505 after surgery, length of hospital stay, and quality of daily life scores), the means or  
506 medians will be compared between the two groups using t- or non-parametric tests as

507 appropriate.

508 Categorical variables including the occurrence of post-operative nausea and  
509 vomiting, respiratory depression, surgeon and patient satisfaction, and the incidence  
510 of CPTP at 6 and 12 months after surgery will be compared using the chi-square test  
511 or logistic regression.

512 The safety of intravenous paracetamol and mannitol will be evaluated; this will  
513 include the incidence of adverse events and complications. The chi-squared or  
514 Fisher's exact tests will be used to determine differences between the two groups.

### 515 **Missing data handling**

516 Missing data will be handled using appropriate methods (such as multiple imputation  
517 or sensitivity analysis) to assess the impact of missing data on the results.

### 518 **Subgroup analysis**

519 Subgroup analyses may be conducted based on relevant factors (such as age, sex, type  
520 of lung cancer, and preoperative pain scores) to explore potential effect modifiers.

### 521 **Multiplicity adjustment**

522 To control the overall type I error rate, adjustment for multiple comparisons may be  
523 considered using methods such as the Bonferroni correction.

### 524 **Interim analysis**

525 Interim analyses will be conducted when 50% and 75% of patients complete the  
526 3-month follow-up, focusing on the primary outcome and safety concerns. An  
527 independent Data and Safety Monitoring Board (DSMB) will review these results and  
528 provide recommendations. The trial may be stopped early based on statistically



529 significant differences in the incidence of CPTP, safety concerns, or futility, with the  
530 final decision made by the Principal Investigator in consultation with the DSMB.

### 531 **Intent-to-treat (ITT) analysis**

532 An ITT analysis will be performed to reduce the impact of bias and increase reliability  
533 of the results. Data processing and statistical analysis will be performed in strict  
534 adherence with the principles of ITT analysis. All participants will be grouped  
535 according to the initial random allocation, regardless of full adherence to the  
536 treatment protocol. Appropriate methods will be employed to handle any missing data;  
537 this will ensure reliability and objectivity of the analysis. For instance, in cases where  
538 a participant has missing follow-up data, suitable methods such as sensitivity analysis  
539 will be used based on the initial grouping to assess the impact on the results;  
540 appropriate explanations will also be provided during result interpretation.

541

### 542 **Interventions: modifications**

543 All protocol modifications, including changes to eligibility, outcomes, or analyses,  
544 will be promptly communicated to investigators, submitted to the Research Ethics  
545 Committees (REC)/IRB for approval with detailed rationale and impact assessment,  
546 disclosed to participants via updated informed consent, updated in trial registry  
547 (Chictr.org.cn.) for transparency, reported in publications, and documented with  
548 access for investigators and the trial team to ensure compliance and transparency.

549

### 550 **Interventions: adherence**

551 In this trial, strategies such as education and training, regular monitoring and  
552 follow-up, provision of support tools like a calendar, establishment of 24-hour  
553 communication channels, and consideration of rewards and incentives will be used to  
554 improve patient compliance with the intervention, ultimately ensuring the accuracy  
555 and effectiveness of the research results.

556

### 557 **Interventions: concomitant care**

558 During the trial, participants will be allowed to receive routine analgesic therapy,  
559 including morphine or other common analgesics, as well as non-interventional pain  
560 management methods. They will also be able to receive necessary rehabilitation  
561 programs and postoperative care guidance. However, they will be prohibited from  
562 taking other experimental analgesic drugs or treatments and from participating in  
563 other clinical research projects simultaneously, to ensure the accuracy of the results of  
564 this trial.

565

### 566 **Ancillary and post trial care**

567 Participants in this study will receive standard of care for lung cancer and  
568 post-thoracotomy pain management, as well as necessary ancillary care throughout  
569 the trial and a reasonable post-trial period. Post-trial, they will transition back to  
570 regular care providers, with the study team remaining available for guidance and  
571 support. A comprehensive compensation plan is in place to protect participants' rights  
572 and welfare, covering medical expenses and other reasonable costs in case of harm

573 directly attributable to trial participation. Adverse events will be promptly reported,  
574 investigated, and resolved, with the study sponsor initiating timely and fair  
575 compensation when necessary.

576

## 577 **Ethics and dissemination**

578 This trial has been approved by the Ethics Committee of the Henan Provincial Chest  
579 Hospital & Chest Hospital of Zhengzhou University on April 29, 2023 (approval  
580 number: (2023) EC (04-06)]. The medical ethics approval can be found in Supporting  
581 information S3. Written and informed consent will be obtained from all participants  
582 prior to their inclusion in this trial. All participants will be provided with detailed  
583 information regarding the study objectives, procedures, potential risks and benefits,  
584 confidentiality measures, and their right to withdraw from the study at any time. The  
585 confidentiality and privacy of participants will be strictly maintained throughout this  
586 trial, and it will be conducted in accordance with ethical principles and regulations to  
587 ensure that the rights and well-being of all participants are protected.

588 The results of this trial will be communicated to the participants and subsequently  
589 submitted for publication in peer-reviewed journals for wider dissemination. The  
590 investigators will actively participate in relevant academic conferences and seminars  
591 to share research methodologies and achievements with peers; this will foster  
592 academic exchange and collaboration.

593

## 594 **Discussion**

595 The combination of intravenous paracetamol and mannitol characteristically  
596 demonstrates rapid onset (peak time of 15 min), high blood drug concentrations ( $C_{\max}$   
597 of 25–30  $\mu\text{g/mL}$  for a single adult dose of 1000 mg injection), lack of first-pass effect,  
598 predictable pharmacokinetics, broad applicability, and efficacy in pain management.  
599 Although the traditional view attributed the analgesic action of paracetamol to  
600 cyclooxygenase inhibition [22], recent research indicates that the primary mechanism  
601 involves the metabolism of N-acylphenol amine (AM404), which subsequently  
602 interacts with transient receptor potential vanilloid 1 and cannabinoid 1 receptors in  
603 the brain. The paracetamol metabolite (AM404) directly induces analgesia via the  
604 transient receptor potential vanilloid 1 receptor at the C-fiber terminals in the spinal  
605 dorsal horn [23]. In view of the characteristics and mechanisms of action, the novel  
606 combination of intravenous paracetamol and mannitol demonstrates superior  
607 analgesic effects and a lower incidence of adverse reactions; this makes it a safe and  
608 effective option for pain management. This trial will therefore aim to evaluate the  
609 efficacy and safety of the combination in managing CPTP; the results are expected to  
610 provide providing valuable insights for future clinical practice.

611 This trial will focus on effective data collection and accurate interpretation of  
612 clinical outcomes, as the effectiveness of data collection is essential for research  
613 reliability. It is also essential that the issue of missing data is effectively addressed;  
614 transparency will therefore be maintained while reporting the extent of missing data,  
615 and robust strategies (such as data imputation and sensitivity analyses) will be  
616 employed to reduce bias. Rigorous methodology (such as double data entry and

617 validation checks) will be followed to minimize data entry errors and enhance data  
618 quality. The clinical relevance of outcome variations across different cohorts will be  
619 elucidated while interpreting clinical outcomes; this will provide insights into patient  
620 care implications. For instance, superior pain scores in the intervention group may  
621 suggest reduced reliance on analgesics; this can minimize medication-related adverse  
622 effects. Our analysis will contextualize the clinical significance of findings; this will  
623 enable comparisons with findings in existing literature, and thereby improve  
624 comprehension and applicability. As it is crucial to address study limitations  
625 (including potential bias related to selection and information), these will be discussed  
626 and their impact on outcomes will be evaluated; this will help ensure that the  
627 interpretations are comprehensive. Adequate sample size determination is key to  
628 robust statistical analyses and reliable conclusions. The rationale behind sample size  
629 determination has therefore been discussed; the impact of sample size inadequacy on  
630 study outcomes has also been described.

631 The findings of this study will have significant clinical implications as it aims to  
632 evaluate the efficacy of a new combination, namely, intravenous acetaminophen and  
633 mannitol, in managing CPTP following surgery for lung cancer. The findings will  
634 have the potential to influence clinical practice in several key ways. First,  
635 confirmation of the effectiveness of acetaminophen and mannitol in alleviating CPTP  
636 could help optimize clinical treatment strategies. This new treatment option may be  
637 integrated into post-operative pain management protocols for those undergoing lung  
638 cancer surgery, and may thereby enhance patient care. Second, confirmation of

639 superiority of the combination could help reduce the use of propofol and remifentanyl  
640 for analgesia. This may in turn reduce the frequency of drug-related side effects and  
641 complications, and thereby improve post-operative comfort and expedite recovery;  
642 this may provide substantial clinical benefits. Finally, evaluation of the impact of the  
643 novel combination on quality of life will offer a more comprehensive understanding  
644 of the post-operative experience. If intravenous acetaminophen and mannitol are  
645 found to improve patient quality of life, the findings could provoke renewed focus on  
646 post-operative care practices and enhance overall patient well-being.

## 647 **Conclusion**

648 In conclusion, this study protocol outlines a rigorous and comprehensive approach  
649 for evaluating the efficacy and safety of intravenous paracetamol and mannitol in  
650 managing CPTP after surgery for lung cancer. The study will employ a randomized  
651 double-blind controlled design to provide reliable evidence regarding the potential  
652 benefits of this treatment approach. The findings will contribute to the existing  
653 literature on CPTP management, and may have important implications for improving  
654 patient outcomes and quality of life.

655

## 656 **Strengths and limitations**

657 The rigorous design of this trial (single-center, randomized, double-blind, and  
658 controlled) will ensure high standards for evaluating drug efficacy. Randomization  
659 and blinding will minimize bias, and the control group will allow for direct  
660 comparison to accurately assess efficacy. Standardized pain assessment tools will

661 ensure consistency and reliability of outcome measurements. In addition, the  
662 single-center design will minimize variability and improve internal validity; however,  
663 this may limit generalizability.

664 The limitations of this trial include potential issues with the sample size, selection  
665 bias, generalizability, compliance, and the resource-intensive nature of design and  
666 execution.

667

#### 668 **Author contributions**

669 JZ and XL will jointly contribute to the design and financial support of this trial, and  
670 have also jointly contributed to writing and revision of the manuscript. These two  
671 authors have contributed equally to the work and are co-first authors. JG and SL will  
672 be responsible for data analysis and will provide relevant research recommendations.  
673 WZ and GX will be responsible for the specific implementation of the research  
674 program. YG will assist in data collection. HX will be responsible for the design and  
675 quality control of the study, provide relevant research suggestions, and participate in  
676 manuscript revision. All authors will contribute to the completion of the study and the  
677 writing of the manuscript. All authors agree to be accountable for the content of the  
678 work.

679

#### 680 **Acknowledgements**

681 The authors would like to thank Xia Gao and Xiao-bo Wang for their contributions to  
682 research quality assurance and data validation.

683

684 **Supporting information**

685 S1 Checklist. SPIRIT checklist.(DOC)

686 S1 Protocol. Study protocol.(DOCX)

687 S2 The template for the informed consent form

688 S3 Medical Ethics Approval

689

690 **Patient and public involvement**

691 Patients and/or the public were not involved in the design, or conduct, or reporting, or  
692 dissemination plans of this trial.

693

694 **Patient consent for publication**

695 Not required.

696

697 **References**

698 1. Lopes A, Seligman Menezes M, Antonio Moreira de Barros G. Chronic  
699 postoperative pain: ubiquitous and scarcely appraised: narrative review. Braz J  
700 Anesthesiol. 2021;71: 649-655.

701 2. Marshall K, McLaughlin K. Pain management in thoracic surgery. Thorac  
702 Surg Clin. 2020;30: 339-346.

703 3. Gupta R, Van De Ven T, Pyati S. Post-thoracotomy pain: current strategies for  
704 prevention and treatment. Drugs. 2020;80: 1677-1684.




- 705 4. Schug SA, Lavand'homme P, Barke A, Korwisi B, Rief W, Treede RD. The  
706 IASP classification of chronic pain for ICD-11: chronic postsurgical or  
707 posttraumatic pain. *Pain*. 2019;160: 45-52.
- 708 5. Reznik SI. Post-thoracotomy pain and nerve protection: back to the drawing  
709 board? *J Thorac Cardiovasc Surg*. 2019;157: 376-377.
- 710 6. Wildgaard K, Ravn J, Kehlet H. Chronic post-thoracotomy pain: a critical  
711 review of pathogenic mechanisms and strategies for prevention. *Eur J*  
712 *Cardiothorac Surg*. 2009;36: 170-180.
- 713 7. Fortier S, Hanna HA, Bernard A, Girard C. Comparison between systemic  
714 analgesia, continuous wound catheter analgesia and continuous thoracic  
715 paravertebral block: a randomised, controlled trial of postthoracotomy pain  
716 management. *Eur J Anaesthesiol*. 2012;29: 524-530.
- 717 8. Mijatovic D, Bhalla T, Farid I. Post-thoracotomy analgesia. *Saudi J Anaesth*.  
718 2021;15: 341-347.
- 719 9. Coppens S, Eochagain AN, Hoogma DF, Dewinter G. Stranger things: the  
720 erector spinae block, extra sensory perception, or paranormal block by proxy?  
721 *APS*. 2023;1:12. doi: 10.1007/s44254-023-00007-5.
- 722 10. Pasero C, Stannard D. The role of intravenous acetaminophen in acute pain  
723 management: a case-illustrated review. *Pain Manag Nurs*. 2012;13: 107-124.
- 724 11. American Society of Anesthesiologists Task Force on Acute Pain  
725 Management. Practice guidelines for acute pain management in the  
726 perioperative setting: an updated report by the American society of

- 727           anesthesiologists task force on acute pain management. *Anesthesiology*.  
728           2012;116: 248-273.
- 729    12.   Singla NK, Hale ME, Davis JC, Bekker A, Gimbel J, Jahr J, et al. IV  
730           acetaminophen: efficacy of a single dose for postoperative pain after hip  
731           arthroplasty: subset data analysis of 2 unpublished randomized clinical trials.  
732           *Am J Ther*. 2015;22: 2-10.
- 733    13.   Nishimoto RN. OFIRMEV: an old drug becomes new again. *Anesth Prog*.  
734           2014;61: 99-102.
- 735    14.   Ghaffarpasand F, Dadgostar E, Ilami G, Shoaee F, Niakan A, Aghabaklou S,  
736           et al. Intravenous acetaminophen (paracetamol) for postcraniotomy pain:  
737           systematic review and meta-analysis of randomized controlled trials. *World*  
738           *Neurosurg*. 2020; 134: 569-576.
- 739    15.   Nonaka T, Hara M, Miyamoto C, Sugita M, Yamamoto T. Comparison of the  
740           analgesic effect of intravenous acetaminophen with that of flurbiprofen axetil  
741           on post-breast surgery pain: a randomized controlled trial. *J Anesth*. 2016;30:  
742           405-409.
- 743    16.   Dastan F, Langari ZM, Salamzadeh J, Khalili A, Aqajani S, Jahangirifard A. A  
744           comparative study of the analgesic effects of intravenous ketorolac,  
745           paracetamol, and morphine in patients undergoing video-assisted  
746           thoracoscopic surgery: a double-blind, active-controlled, randomized clinical  
747           trial. *Ann Card Anaesth*. 2020;23: 177-182.
- 748    17.   Sharma CV, Long JH, Shah S, Rahman J, Perrett D, Ayoub SS, et al. First

- 749 evidence of the conversion of paracetamol to AM404 in human cerebrospinal  
750 fluid. *J Pain Res.* 2017;10: 2703-2709.
- 751 18. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al.  
752 SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical  
753 trials. *BMJ.* 2013;346: e7586.
- 754 19. Karcioğlu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the  
755 pain scales in adults: which to use? *Am J Emerg Med.* 2018;36: 707-714.
- 756 20. Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in  
757 patients with cancer: a focused review. *Indian J Palliat Care.* 2011;17:  
758 108-115.
- 759 21. Chow SC, Shao J, Wang H. Sample size calculation in clinical research. 2nd  
760 Ed. New York: Chapman & Hall/CRC Press; 2007.
- 761 22. Ayoub SS. Paracetamol (acetaminophen): A familiar drug with an unexplained  
762 mechanism of action. *Temperature (Austin).* 2021;8: 351-371.
- 763 23. Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known  
764 and novel mechanisms of action. *Front Pharmacol.* 2020;11: 580289.
- 765

**FIGURE 1.** Flow diagram of patients.



**Fig 1. Schedule of patient enrollment, study interventions, and outcomes assessments.**

Time point	Study period									
	Enrollmen t	Allocati on	Post-allocation						Close-o ut	
	Pre-anesth esia visit	Prior to anesthes ia	PAC U entr y	30 min after PAC U entr y	12 h after surge ry	24 h after surge ry	48 h after surge ry	3 mont hs after surge ry	6 mont hs after surge ry	12 months after surgery
<b>Enrollment</b>	—	—	—	—	—	—	—	—	—	—
<b>Eligibility criteria</b>	×	—	—	—	—	—	—	—	—	—
<b>Written informed consent</b>	×	—	—	—	—	—	—	—	—	—
<b>Demograph ic data</b>	×	—	—	—	—	—	—	—	—	—
<b>Baseline characteristi</b>	×	—	—	—	—	—	—	—	—	—

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.27.24312675>; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

<b>cs</b>										
<b>Randomizat</b>	—	×	—	—	—	—	—	—	—	—
<b>ion</b>										
<b>Allocation</b>	—	×	—	—	—	—	—	—	—	—
<b>Interventio</b>	—		—	—	—	—	—	—	—	—
<b>ns</b>										
<b>Intravenous</b>	—	×	—	—	—	—	—	—	—	—
<b>paracetamol</b>										
<b>and</b>										
<b>mannitol</b>										
<b>Normal</b>	—	×	—	—	—	—	—	—	—	—
<b>saline</b>										
<b>Assessment</b>	—	—	—	—	—	—	—	—	—	—
<b>Dosage of</b>	—	—	×	—	—	—	—	—	—	—
<b>propofol</b>										
<b>Dosage of</b>	—	—	×	—	—	—	—	—	—	—
<b>remifentanil</b>										
<b>NRS pain</b>	—	—	×	×	×	×	×	×	×	×
<b>scores</b>										
<b>Number of</b>	—	—	—	—	—	×	×	—	—	—
<b>times PCIA</b>										
<b>is pressed</b>										

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.27.24312675>; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

---

Nausea and vomiting	—	—	—	—	—	—	×	—	—	—
Headache	—	—	—	—	—	—	×	—	—	—
Insomnia	—	—	—	—	—	—	×	—	—	—
Itching	—	—	—	—	—	—	×	—	—	—
Respiratory depression	—	—	—	—	—	—	×	—	—	—
Excessive sedation	—	—	—	—	—	—	×	—	—	—
Urinary retention	—	—	—	—	—	—	×	—	—	—
Allergic reactions	—	—	—	—	—	—	×	—	—	—
Liver injury	—	—	—	—	—	—	×	—	—	—
Kidney injury	—	—	—	—	—	—	×	—	—	—
Surgeon satisfaction	—	—	—	—	—	—	×	—	—	—
Patient satisfaction	—	—	—	—	—	—	—	—	—	×
Quality of daily life	—	—	—	—	—	—	—	—	—	×

---

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.27.24312675>; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

According to the SPIRIT 2013 statement defining the standard items for clinical research programs.  
NRS, numerical rating scale. PCIA, patient-controlled intravenous analgesia.

medRxiv preprint doi: <https://doi.org/10.1101/2024.08.27.24312675>; this version posted August 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  
It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .